Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05407701 · ClinicalTrials.gov registry record · NA

Cranberry Ingestion and Cycling Related Immunity and Inflammation

A NA study of Inflammatory Response and Metabolic Disturbance, sponsored by Appalachian State University.

Completed
Registry status
NA
Development phase
29
Enrollment target
1
Study location

NCT05407701: Completed NA study of Inflammatory Response and Metabolic Disturbance, sponsored by Appalachian State University.

NCT05407701 is a NA study of Inflammatory Response and Metabolic Disturbance that has completed, run by Appalachian State University. The registered enrollment target is 29 participants, below the 176-participant average among 16 other Inflammatory Response trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05407701, a NA study of Inflammatory Response and Metabolic Disturbance, has completed, sponsored by Appalachian State University.

COMPLETED
Registry status
NA
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, crossover clinical trial with 25 male and female cyclists. Study participants will ingest polyphenol-rich cranberry juice or placebo juice for 4 weeks under double-blinded procedures, and then crossover to the opposite supplement. The primary objective of this study is to examine the efficacy of 4-weeks ingestion of cranberry juice in moderating exercise-induced inflammation, immune dysfunction, and muscle damage. Outcome measures will include global proteiomics, oxylipins, and cytokines.

Primary Outcome

The mitogenic response of lymphocytes will be determined in whole blood culture using suboptimal mitogen (Concanavalin A) doses

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Cranberry Juice

Study Locations (1)

North Carolina

  • Appalachian State University Human Performance Lab, North Carolina Research Campus - Kannapolis

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2022-06-01
Est. Completion 2023-01-15
Phase NA
Appalachian State University

37 total trials

What the finished NCT05407701 record still lists

NCT05407701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 176-participant average among 16 other Inflammatory Response trials with a reported enrollment target (84% lower).

The record links to 3 conditions, with Inflammatory Response appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05407701 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05407701 about?

NCT05407701 is a clinical study titled "Cranberry Ingestion and Cycling Related Immunity and Inflammation". This is a randomized, crossover clinical trial with 25 male and female cyclists. Study participants will ingest polyphenol-rich cranberry juice or placebo juice for 4 weeks under double-blinded procedures, and then crossover to the opposite supplement. The primary objective of this study is to exami...

What is the current status of trial NCT05407701?

This trial is currently completed. It is a NA study. The enrollment target is 29 participants. The study started on 2022-06-01. Estimated completion is 2023-01-15.

What conditions does trial NCT05407701 study?

This clinical trial studies the following conditions: Inflammatory Response, Metabolic Disturbance, Immune Suppression.

What interventions are being tested in trial NCT05407701?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Cranberry Juice (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05407701?

This trial is sponsored by Appalachian State University, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05407701 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammatory Response

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05407701's enrollment target sits among peer trials

29 16th of 16 higher than 1 of 16 other Inflammatory Response trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Inflammatory Response trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05407701, the US trial registry maintained by the National Library of Medicine. NCT05407701 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.